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Abstract 
 
Endothelial dysfunction is a powerful surrogate marker of 
cardiovascular risk. Flow-mediated dilation (FMD) is an indicator of 
endothelial function and is identified as an independent predictor of future 
cardiovascular events in clinical settings. Nicorandil, an anti-angina agent 
with ATP-sensitive potassium channel (KATP channel) opening and 
nitrate-like activity, has been shown to improve the prognoses of patients 
with stable angina pectoris via several mechanisms, including endothelial 
protective effects. Although patients with angina have many risks for 
endothelial dysfunction, such as diabetes and drug-eluting stent, it has not 
been also fully understood about the risks that nicorandil is effective against. 
The purpose of this study is to evaluate the endothelial protection provided 
by nicorandil against two risk factors, diabetes and paclitaxel. Paclitaxel was 
used for drug-eluting stent. Furthermore, I tried to evaluate the endothelial 
function by FMD. 
In chapter 1, I examined the effect of nicorandil on diabetic 
endothelial dysfunction. Male Sprague-Dawley rats were intraperitoneally 
injected with streptozotocin (STZ) to induce diabetes. Nicorandil and tempol 
were administered in drinking water for one week, starting 3 weeks after 
STZ injection. Endothelial function was evaluated by measuring FMD in the 
femoral arteries of anaesthetized rats. Femoral arteries were harvested and 
protein expression was analyzed by western blotting. High glucose-induced 
reactive oxygen species (ROS) production was measured in cultured human 
coronary artery endothelial cells (HCAECs). I could observe the reduction of 
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FMD in diabetic rats, which was improved by nicorandil or tempol. NADPH 
oxidase and endothelial nitric oxide synthase (eNOS) uncoupling were 
increased in femoral arteries of diabetic rats, which were inhibited by 
nicorandil. High glucose-induced ROS production in HCAECs was inhibited 
by nicorandil, N-omega-nitro-L-arginine methyl ester (L-NAME) or 
apocynin.  
In chapter 2, I examined the effect of nicorandil on paclitaxel-induced 
endothelial dysfunction. An osmotic pump was implanted subcutaneously 
into a small pouch between the shoulder blades of rats to continuously infuse 
paclitaxel. Nicorandil, diazoxide, isosorbide dinitrate (ISDN) or tempol were 
administered for 1 week from just after implantation of the osmotic pump. 
FMD was measured at 1 week after implantation of the osmotic pump. 
Femoral arteries were harvested for real-time PCR. ROS production by 
paclitaxel was measured in HCAECs and in vivo in the mice. I could observe 
the reduction of FMD by paclitaxel, and nicorandil, diazoxide and tempol, 
but not ISDN, improved the reduction of FMD. NADPH oxidase was 
increased in femoral arteries by paclitaxel, which was inhibited by nicorandil. 
Paclitaxel-induced ROS production in HCAECs was inhibited by nicorandil. 
This effect was reduced by 5-HD, but not ODQ. ROS production was also 
observed in vivo mice treated with paclitaxel, which could be prevented by 
nicorandil. 
In the present study, I demonstrated that nicorandil improved the 
reduction of FMD through its anti-oxidative effect in diabetic and 
paclitaxel-treated rats. Moreover, the anti-oxidative effect of nicorandil 
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might be exerted via KATP channel opening. Therefore, nicorandil may 
improve the prognoses of angina patients with concomitant diabetes and 
drug-eluting stent treatment by protecting their endothelial function. 
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Abbreviations 
 
ADMA: asymmetric dimethylarginine 
BH4: tetrahydrobiopterin 
DAF-2DA: Diaminofluorescein-2 diacetate 
DCF: 2’, 7’-dichlorofluorescein 
DES: drug-eluting stent 
EDHF: endothelium-derived hyperpolarization factor 
eNOS: endothelial nitric oxide synthase 
FMD: flow-mediated dilation 
GCH-1: GTP cyclohydrolase 1 
HCAECs: human coronary artery endothelial cells 
H2DCF-DA: 2', 7'-dichlorodihydrofluorescein diacetate 
ISDN: isosorbide dinitrate 
KATP channel: ATP-sensitive potassium channel 
L-NAME: N-omega-nitro-L-arginine methyl ester 
NF-B: nuclear factor-kappa B 
NO: nitric oxide 
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NOx: nitrate and nitrite 
NTG: nitroglycerin 
ODQ: 1H-[1,2,4] oxadiazolo [4,3-a]quinoxalin-1-one 
PAI-1: plasminogen activator inhibitor 
PES: paclitaxel-eluting stent 
PKC: protein kinase C 
PVDF: polyvinylidene difluoride 
ROS: reactive oxygen species 
STZ: streptozotocin 
Tempol: 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl 
5-HD: 5-hydroxydecanoate 
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General Introduction 
It has become evident that the endothelium plays a crucial role in 
regulating vascular tone and structure. Common conditions that predispose 
to atherosclerosis, such as diabetes, hypertension, hypercholesterolemia, are 
associated with endothelial dysfunction. They may be linked to 
proinflammatory and prothrombotic endothelial phenotypes (Landmesser et 
al., 2004). Alterations in endothelial function play a pivotal role in the 
development and progression of atherosclerosis and its clinical complications. 
Therefore, endothelial dysfunction is a powerful surrogate marker of 
cardiovascular risk, and the severity of endothelial dysfunction correlates 
with a patient’s risk for experiencing an initial or recurrent cardiovascular 
event (Widlansky et al., 2003). 
Clinically, endothelial function generally has been evaluated by 
endothelium-dependent relaxation. Flow-mediated dilation (FMD) is an 
established method for assessing endothelial function (Celermajer et al., 
1992). It is determined from the dilation of conduit arteries following 
temporary ischemia and reperfusion by release of a forearm-occluding cuff 
and. Temporary ischemia induces dilation of the downstream 
microvasculature, then reperfusion increases blood flow (i.e., reactive 
hyperemia) and wall shear stress (Kelm, 2002; Pyke and Tschakovsky, 2005). 
These lead to a rapid activation of endothelial nitric oxide synthase (eNOS) 
that increases formation of nitric oxide (NO), leading to vasodilation (Rassaf 
et al., 2006). Endothelial function can be evaluated noninvasively using this 
technique. FMD also has been used to evaluate endothelial function in dogs 
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and pigs (Jones et al., 2011; Weber et al., 2011). Recently, Heiss et al. 
reported a method to measure endothelial function by FMD in rats (Heiss et 
al., 2008). 
 Nicorandil is an antiangina agent with ATP-sensitive potassium 
channel (KATP channel) opening and nitrate-like activity. Nicorandil has been 
shown to improve the prognoses of patients with stable angina pectoris by 
preconditioning-like cardioprotective effects in the IONA study and the 
JCAD study (Horinaka et al., 2010; IONA study group, 2002). In addition to 
the preconditioning-like cardioprotective effects, some recent reports 
demonstrated that nicorandil can exert endothelial protective effects. 
Long-term administration of nicorandil significantly improved endothelial 
function in patients with ischemic heart disease or with cardiovascular risk 
factors, as evaluated by FMD in forearm arteries (Ishibashi et al., 2008; 
Sekiya et al., 2005). In swine heart, nicorandil reduced myocardial no-reflow 
after ischemia reperfusion by protecting endothelial function (Zhao et al., 
2006). In human umbilical vein endothelial cells, nicorandil inhibited 
apoptosis induced by serum starvation by inhibiting production of reactive 
oxygen species (ROS) (Date et al., 2005). Therefore, it is believed that 
nicorandil can improve the prognoses of patients with angina due, in part, to 
protecting endothelial function. However, the endothelial protective 
mechanisms of nicorandil have not been fully understood. Moreover, the risk 
factors of endothelial dysfunction against which nicorandil is effective are 
not clear. 
 Patients with angina have multiple risk factors for endothelial 
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dysfunction, such as diabetes, hypertension, hypercholesterolemia, smoking, 
aging and obesity (Celermajer et al., 1992; Sorensen et al., 1994; Steinberg et 
al., 1996; Widlansky et al., 2003). In addition to these traditional risk factors, 
drug-eluting stent (DES) recently have been considered as another potential 
cause of endothelial dysfunction. DES, which is used for percutaneous 
coronary intervention, is coated with anti-proliferative compounds, such as 
paclitaxel to prevent in-stent restenosis. While DES dramatically reduce 
in-stent restenosis (Stone et al., 2004), the potent anti-proliferative agents 
have raised concerns regarding endothelial dysfunction (Shin et al., 2007).  
 Accordingly, the purpose of this study was to elucidate the effects and 
mechanisms on the endothelial protective effect of nicorandil against two 
risk factors. In the chapter 1, I examined the effect of nicorandil on diabetic 
endothelial dysfunction in rats. In the chapter 2, I examined the effect of 
nicorandil on paclitaxel-induced endothelial dysfunction in rats. In these 
studies, I tried to evaluate the endothelial function by measurement of FMD 
in living rats. 
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Chapter 1 
 
 
Studies of effect of nicorandil  
on diabetic endothelial dysfunction in rats 
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1-1. Introduction 
Diabetes mellitus is regarded as an independent major risk factor for 
the development of cardiovascular disease, since long-term survival and 
freedom from cardiac events were reduced in diabetic coronary angioplasty 
patients (Kasai et al., 2008; Kip et al., 1996; The Japanese Coronary Artery 
Disease (JCAD) Study Investigators, 2006). Endothelial dysfunction plays a 
central role in diabetic vascular diseases (Creager et al., 2003). A common 
mechanism underlying this endothelial dysfunction could involve increased 
production of ROS in vascular tissue (Gryglewski et al., 1986). High glucose 
greatly increases endothelial superoxide production (Cai et al., 2005), 
leading to an eNOS uncoupling state, followed by lower production of NO 
and more ROS production, which acts to quench NO (d’Uscio et al., 2003; 
Landmesser et al., 2003; Laursen et al., 2001; Tiefenbacher et al., 2000; 
Vasquez-Vivar et al., 2002). Reduced NO availability attenuate its beneficial 
vascular effects such as vasodilation, regulation of vascular smooth muscle 
proliferation and expression of cellular adhesion molecules that are involved 
in initiating atherosclerotic plaque formation (Bian et al., 2008). Therefore, 
increased ROS production with diabetes has been speculated to reduce 
endothelial NO availability, leading then to endothelial dysfunction 
(Landmesser et al., 2004; Nakagawa et al., 2011). 
Nicorandil is an anti-angina agent that opens KATP channels and acts 
like nitrate compounds. It reportedly improves prognoses in patients with 
angina pectoris via preconditioning effects (IONA study group, 2002). This 
beneficial effect of nicorandil is exerted across a broad range of patients with 
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stable angina, for example in diabetic patients (IONA study group, 2004). In 
general, however, the preconditioning effect is abolished in diabetic animals 
(Miki et al., 2009; Katakam et al., 2007) and humans (Ishihara et al., 2001). 
Therefore, it is believed that the cardioprotective effect of nicorandil is 
mediated by the other mechanisms. Recently, nicorandil has been shown to 
exert endothelial protective effects in both clinical settings and animal 
studies. Therefore, I hypothesized that nicorandil can prevent diabetic 
endothelial dysfunction.  
In the present study, I investigated the protective effect of nicorandil on 
endothelial function in rats with diabetes induced by streptozotocin (STZ). 
Endothelial function was evaluated by measuring FMD in femoral arteries 
using a high-resolution ultrasound system under in vivo conditions in which 
blood flow, many humoral factors and nerve activity were maintained. The 
mechanism underlying the protective action of nicorandil also was 
investigated in relation to ROS production in the endothelium, both in vivo 
and in vitro. 
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1-2. Materials and Methods 
Animals  
Male Sprague-Dawley rats (Charles River Japan, Yokohama, Japan, 6 
weeks old, 200-240 g) were used in all experiments. All rats were fed 
ordinary laboratory chow and allowed free access to water under a constant 
light and dark cycle of 12 h. Diabetes was induced by intraperitoneal 
administration of STZ (40 mg/kg, Wako Pure Chemicals Co., Osaka, Japan) 
once a day for 3 days. Glucose concentrations were measured one week after 
STZ administration. Diabetes was considered to have been induced when the 
glucose level was higher than 250 mg/dL. Nicorandil 
[N-(2-hydroxyethyl)nicotinamide nitrate ester] was synthesized in the 
Chugai Organic Chemistry Laboratory. Nicorandil (15 mg/kg/day) and 
4-hydroxy-2,2,6,6- tetramethylpiperidine-N-oxyl (tempol, 20 mg/kg/day, 
Sigma-Aldrich, St. Louis, MO, USA) were administered in drinking water for 
one week, starting 3 weeks after STZ administration.  
All animal procedures were conducted in accordance with Chugai 
Pharmaceutical's ethical guidelines for animal care, and all experimental 
protocols were approved by the Animal Care Committee of the institution 
and conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National institutes of Health. 
 
Measurement of FMD 
Blood pressure (tail-cuff method, BP-98A Softron, Tokyo, Japan) and 
blood glucose were measured four weeks after STZ administration, and the 
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rats were anaesthetized with thiobutabarbital with constant monitoring of 
rectal temperature. A catheter was inserted into the jugular vein to 
administer drugs. The animals were kept stable with a heated sheet and 
warming lamps.  
FMD measurement in rats was described previously (Heiss et al., 2008). 
The diameter of femoral arteries and Doppler flow were measured using a 
high-resolution ultrasound system (Vevo 770, VisualSonics, Toronto, 
Canada). The femoral artery was visualized with a 30- or 40-MHz transducer. 
After identifying the femoral artery by its characteristic flow pattern, the 
position of the probe was optimized to clearly show the vessel wall/lumen 
interfaces and then fixed throughout the investigations. Experiments were 
started over an equilibration period of 15 min and when body core 
temperature was stable (37  1C). 
Ultrasound measurements of diameter and Doppler-flow were obtained 
from longitudinal sections of the femoral artery before and after 5 min of 
hindlimb ischemia. Ischemia and reperfusion of the hindlimb were achieved 
with a snare occluder positioned upstream from the site to be visualized, 
around the common iliac artery, through a trans-abdominal access. The 
snare occluder consisted of a 5-0 nylon surgical suture around the artery that 
was passed through a 4 cm PE-200 tube, and the skin was closed with 
surgical clips. Hindlimb ischemia was created by pulling on the filament 
through the tube and clamping it. 
Baseline recordings were taken after an equilibration period, and then 
the common iliac artery was occluded with the snare occluder. Flow arrest 
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was confirmed by abrogation of the Doppler signal. After 5 min of ischemia, 
the hindlimb was reperfused by releasing the occluder. The changes in flow 
velocity and the diameter of the femoral artery were monitored at 0, 0.5, 1, 2 
and 3 min after reperfusion. In this study, FMD was defined as the peak 
change in femoral artery diameter measured at 1 min after reperfusion. The 
clinical guideline to assess FMD defined the peak change in brachial artery 
diameter as an endothelial function, which occurred about 1 min after 
reperfusion (Corretti et al., 2002). 
To evaluate endothelium-independent vasodilation, nitroglycerin (NTG) 
was administered to the same rats after FMD measurement, with 10 min 
breaks between measurements. After obtaining baseline recordings of 
diameter, NTG (5 g/kg) was administered intravenously via the jugular vein 
catheter. Changes in femoral artery diameter were monitored at 10, 30, 60 
and 120 sec after administration.  
 
Western blot analysis 
Femoral arteries were harvested and frozen in liquid N2 immediately 
after isolation and stored in a -80C freezer until protein expression was 
measured by Western blotting. The femoral artery was homogenized in a 
homogenization buffer composed of 25 mM Tris-HCl (pH 7.4), 1 mM 
dithiolthreitol, 25 mM sodium fluoride, 1 mM sodium orthovanadate, 
protease inhibitor cocktail tablet, phosphatase inhibitor cocktail and 1% 
Triton X-100. The homogenates were centrifuged at 14,000 g for 20 min at 
4C. Supernatants were collected, and protein concentrations were 
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determined using a BCA Protein Assay Kit (Thermo Scientific, Woltham, 
USA). Equal amounts of protein extracts were separated on 10% 
SDS-polyacrylamide gel and immobilised on polyvinylidene difluoride 
(PVDF) membranes (Millipore, Billerica, USA). To investigate the eNOS 
uncoupling state, low-temperature SDS-PAGE was performed to detect the 
dimer and monomer of eNOS. Briefly, protein extracts were mixed with 
sample buffer (without -mercaptoethanol), and non-boiled samples were 
separated on SDS-PAGE. The membranes were blocked in a PVDF Blocking 
Reagent (TOYOBO, Osaka, Japan), and incubated with anti-p47phox, 
anti-eNOS (Santa Cruz Biotechnology, Santa Cruz, USA) or anti-GTP 
cyclohydrolase 1 (GCH-1) antibodies (Abnova, Taipei, Taiwan). After 
washing, the membranes were incubated with anti-rabbit or anti-goat IgG 
conjugated with horseradish peroxidise (Santa Cruz Biotechnology). 
Immunoreactive signals were visualized with the SuperSignal West Dura 
Extended Duration Substrate (Thermo Scientific), and detected using a 
ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, USA). Each protein 
signal was normalized to -actin expression from the same sample. 
 
Measurement of serum NOx 
To determine NO excretion, total nitrate and nitrite (NOx) 
concentrations were measured by the Griess method with a Total Nitric 
Oxide Assay Kit (Enzo Life Sciences, Farmingdale, USA). Serum samples 
were diluted 1:2 into reaction buffer and ultra-filtered through a 10,000 
molecular weight cut-off filter. Samples were read at 540 nm with a 
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Microplate Reader (Molecular Devices, Sunnyvale, USA).  
 
Cell culture and treatment 
Normal human coronary artery endothelial cells (HCAECs) were 
purchased from Lonza Inc. (Walkersville, MD, USA). HCAECs at passages 
3-5 were cultured with EBM-2 medium supplemented with 5% fetal bovine 
serum (Lonza). To measure production of ROS, the cells were seeded onto 
plastic dishes (1105 cells/2 mL/dish) and cultured as monolayers in a 5% 
CO2 humidified incubator at 37C overnight. After incubation, the HCAECs 
were exposed to normal (5.6 mM) or high glucose (35.6 mM) for 24 h. 
Nicorandil (100 M), apocynin (100 M, Calbiochem, Darmstadt, Germany) 
or N-omega-nitro-L-arginine methyl ester (L-NAME, 300 M, St Louis, 
Sigma-Aldrich) were added over the same period. 
 
Measurement of ROS production using a fluorescent probe in HCAECs 
The production of ROS was monitored using the fluorescent probe 2', 
7'-dichlorodihydrofluorescein diacetate (H2DCF-DA) (Invitrogen, Carlsbad, 
USA). Briefly, cultured cells were incubated with 10 M H2DCF-DA for 45 
min in a 37C incubator, and 2’, 7’-dichlorofluorescein (DCF) fluorescence 
was then quantified by confocal microscopy (Zeiss Axiovert 200) from at least 
20 randomly-selected cells/dish, using three dishes for each experimental 
condition.  
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Statistical analyses 
  All data are expressed as mean  SE. The n values refer to the 
number of individual animals on which experiments were performed. The 
statistical significance of differences was determined using Tukey's Multiple 
Comparison Test. Probability values less than 0.05 were considered 
significant. Statistical analyses were performed using SAS version 8.2 
software (SAS Institute, Cary, USA). 
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1-3. Results  
Animals  
  Body weight, blood glucose, blood pressure and heart rate are shown 
in Table 1. Body weight increased in each group of rats for 4 weeks after STZ 
administration, although the increase in the STZ rats was smaller than in 
normal rats. Blood glucose levels in STZ rats were significantly higher than 
in normal rats. Systolic blood pressure was slightly increased, while heart 
rate decreased significantly in STZ rats. Nicorandil appeared not to 
influence any of these parameters in STZ rats. 
  
  
19 
 
 
 
 
 
 
 
Table 1. Body weight, blood glucose, blood pressure and heart rate at 4 weeks 
after STZ administration 
 
 normal STZ STZ+nicorandil 
N 7 6 6 
Body weight (0 wks, g) 213.2 ± 1.6 212.2 ± 3.4 217.1 ± 4.3 
Body weight (4 wks, g) 417.8 ± 8.7 299.4 ± 15.4* 327.7 ± 9.8* 
Blood glucose (mg/dL) 96.7 ± 1.7 392.3 ± 17.4* 424.5 ± 16.1* 
Systolic blood pressure 
(mmHg) 
121.8 ± 1.8 135.4 ± 5.9 133.5 ± 3.2 
Heart rate (bpm) 359.4 ± 11.9 312.4 ± 14.5* 334.5 ± 11.4 
 
*p<0.05 vs normal 
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FMD in STZ-induced diabetic rats 
  Endothelial function was evaluated by the measurement of FMD in 
rat femoral arteries. Reperfusion after 5-min of hindlimb ischemia instantly 
increased flow velocity (i.e. reactive hyperaemia) compared with baseline 
femoral artery flow, followed by a rapid decay to baseline values at around 3 
min (Fig. 1A). The increase in flow velocity was associated with a delayed 
increase in femoral arterial vasodilation that peaked at 1 min after 
reperfusion (Fig. 1B). This delayed vasodilation in the femoral artery was 
defined as FMD. In STZ rats, peak velocity in the femoral artery was lower 
than that in normal rats (normal, 106.7  5.0; STZ, 49.5  2.5 mm/s; n = 6-7, 
Fig. 1A) at baseline (i.e. before ischemia). However, hyperaemia, expressed 
as the % change in peak velocity just after reperfusion, did not differ between 
normal and STZ rats (Fig. 1D). FMD was lower in STZ rats compared with 
normal rats (normal, 19.5  1.7; STZ, 9.7  1.4%; n = 6-7, Fig. 1B, E). In 
evaluating endothelium-independent vasodilatory potency, intravenous 
administration of NTG led to vasodilation of the femoral artery that peaked 
at 30 sec (Fig. 1C). NTG-induced vasodilation was similar in normal and STZ 
rats (Fig. 1C, F). 
Nicorandil (15 mg/kg/day) was administered in drinking water for one 
week starting 3 weeks after STZ administration to evaluate its effects on 
endothelial function. Nicorandil restored the reduced FMD in STZ rats to 
almost same level as in normal rats (STZ + Nicorandil, 17.7  2.6%; n = 6, Fig. 
1B, E), whereas nicorandil affected neither NTG-induced vasodilation nor 
flow velocity. In normal rats, nicorandil produced no significant changes in 
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FMD (normal, 18.8  4.0; nicorandil, 20.9  1.7%; n = 5-6, Fig. 1G). These 
results demonstrated that nicorandil could ameliorate endothelial 
dysfunction in STZ rats, without changing flow velocity or vascular smooth 
muscle function. 
  
  
22 
 
 
 
Figure 1. Effect of nicorandil on endothelial dysfunction induced in rats by 
STZ 
Ultrasound measurements were performed at 4 weeks after STZ administration. Time 
courses of velocity (A), FMD (B) and NTG-induced vasodilation (C) in rat femoral 
arteries were measured after 5 min ischemia. Percent change in velocity (Δ%, D) and 
NTG-induced vasodilation (F) were similar among groups. FMD peaked at 1 min after 
reperfusion and then decreased in diabetic rats, showing it was improved by nicorandil 
(E). Nicorandil showed no significant changes in FMD of normal rats (G). *p<0.05 vs 
normal, #p<0.05 vs STZ (n = 5-7). The numeral in each column is the number of 
animals.  
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Involvement of oxidative stress in decreased FMD in STZ-induced diabetic 
rats 
  The effect of tempol was investigated to clarify how oxidative stress 
was involved in endothelial dysfunction in rats treated with STZ. Tempol (a 
radical scavenger) significantly reversed the decrease in FMD (STZ, 6.5  
1.5; STZ + Tempol, 13.3  1.4%; n = 6, Fig. 2). Expression of NADPH oxidase 
was measured in femoral arteries of STZ rats because it is a potential source 
of vascular superoxide. In STZ rats, the p47phox protein (a major NADPH 
oxidase component) increased in the femoral artery. Nicorandil prevented an 
increase in expression of p47phox (Fig. 3A). Expression of total eNOS was 
measured in the rat femoral artery to examine how it is associated with 
endothelial dysfunction. Unexpectedly, total eNOS expression increased in 
STZ rat femoral arteries, and the increase was prevented by nicorandil (Fig. 
3B). However, this increase in total eNOS expression did not raise serum 
NOx levels in STZ rats, and nicorandil also showed no significant changes 
(Fig. 4). In oxidative state, reducing tetrahydrobiopterin (BH4) causes eNOS 
uncoupling state, resulting in production of superoxide by eNOS monomer 
(Landmesser et al., 2003). In this study, the eNOS dimer/monomer ratio 
decreased (Fig. 3C), and expression of GCH-I (a synthetase of BH4) also 
decreased in STZ rat femoral arteries (Fig. 3D). Nicorandil restored the 
eNOS dimer/monomer ratio and GCH-1 expression to normal values (Fig. 3C, 
D). 
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Figure 2. Effect of tempol on endothelial dysfunction induced in rats by STZ 
Ultrasound measurements were performed 4 weeks after STZ administration. Data 
indicate the % changes in femoral diameter at 1 min after reperfusion. Tempol lessened 
the decrease in FMD in diabetic rats. #p<0.05 vs STZ (n = 6).   
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Figure 3. Effects of nicorandil on p47phox, total eNOS and GCH-1 expression, 
and eNOS uncoupling in rat femoral arteries 
Femoral arteries were harvested from diabetic rats at 4 weeks after STZ administration. 
Nicorandil decreased the increase in p47phox (A) and total eNOS proteins (B) in the 
arteries. Nicorandil increased the decrease in the eNOS dimer/monomer ratio (C) and 
GCH-1 protein (D) in the arteries. *p<0.05 vs normal, #p<0.05 vs STZ (n = 6-8). The 
numeral in each column means the number of animals. 
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Figure 4. Effect of nicorandil on serum NOx levels in STZ rats 
NO excretion was assessed from serum NOx concentration measured by the Griess 
method. Serum NOx concentrations were not changed among the groups (n = 6-8). The 
numeral in each column is the number of animals. 
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ROS production in HCAECs induced by high glucose 
To clarify the possibility that eNOS itself might serve as a source of 
superoxide in the diabetic state, I examined the influence of the NOS 
inhibitor L-NAME on production of ROS induced by high glucose in HCAECs. 
High glucose increased ROS production indicated as DCF fluorescence in 
HCAECs. Interestingly, L-NAME decreased high glucose-induced ROS 
production in HCAECs (Fig. 5A-D), suggesting that eNOS is an important 
superoxide source in high glucose conditions. Furthermore, apocynin, an 
NADPH oxidase inhibitor, also decreased high glucose-induced ROS 
production in HCAECs (Fig. 5E-H). Therefore, NADPH oxidase is also 
another important superoxide source in high glucose conditions. Moreover, 
the anti-oxidative effect of nicorandil was confirmed because nicorandil 
improved expression of p47phox and eNOS uncoupling state in the femoral 
arteries of STZ rats (Fig. 3A, C). Nicorandil also prevented high 
glucose-induced ROS production in HCAECs (Fig. 6A-D). Taken together, 
these results suggest that nicorandil could exert an anti-oxidative effect by 
normalizing NADPH oxidase and eNOS uncoupling state in endothelial cells. 
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Figure 5. Effect of L-NAME and apocynin on ROS production in HCAECs 
treated with high glucose 
HCAECs were exposed to high glucose (35.6 mM) for 24 h, and L-NAME (300 M) or 
apocynin (100 M) for the same period. These representative images show DCF 
fluorescence in control (A, E), high-glucose (B, F) and high-glucose + L-NAME (C) or + 
apocynin (G). High glucose treatment increased ROS production, which could be 
prevented by L-NAME (D) or apocynin (H). *p<0.05 vs control, #p<0.05 vs high-glucose 
(20 cells/dish from 2-3 dishes). Scale bar = 100 m.   
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Figure 6. Effect of nicorandil on ROS production induced by high-glucose 
treatment in HCAECs 
HCAECs were exposed to high glucose (35.6 mM) for 24 h, and nicorandil (100 M) for 
the same period. Representative images show DCF fluorescence in control (A), 
high-glucose treatment (B) and high-glucose + nicorandil (C). High-glucose treatment 
increased ROS production, which was prevented by nicorandil (D). *p<0.05 vs control, 
#p<0.05 vs high-glucose (20 cells/dish from 3 dishes). Scale bar = 100 m. 
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1-4. Discussion  
The present study demonstrated that nicorandil protected STZ rats 
from endothelial dysfunction assessed by the FMD reduction without 
affecting endothelium-independent vasodilation. Because earlier studies 
showed that endothelial dysfunction in diabetes is caused by increased ROS 
(Gryglewski et al., 1986), there should be 2 possibilities for mechanisms 
underlying endothelial protection. Nicorandil could inhibit the expression 
and activity of NADPH oxidase, a major source of ROS (Griendling et al., 
2000; Muller and Morawietz, 2009). Or, because monomer state of eNOS is a 
source of ROS but not NO depending on the BH4 level (Landmesser et al., 
2003), nicorandil could reduce ROS production by inhibiting the 
monomerization of eNOS through increased expression of BH4 synthase.  
These results suggested that nicorandil improved endothelial function 
in STZ rats through an antioxidative effect exerted by normalizing p47phox 
and eNOS uncoupling. Nicorandil may offer a novel therapy for diabetes 
complications by targeting endothelial dysfunction caused by ROS. 
 
Endothelial dysfunction and NADPH oxidase in diabetes 
Endothelial dysfunction is attributable to endothelial ROS production 
derived from vascular NADPH oxidase, which is an important source of 
superoxide (Griendling et al., 2000; Muller and Morawietz, 2009). The 
present results generally agree with earlier reports that 
endothelial-dependent relaxation of arteries is impaired by NADPH oxidase 
increasing ROS production in both type I (Hink et al., 2001; Ojaimi et al., 
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2010) and type II diabetic models (Gupte et al., 2010; Mishra et al., 2010). 
This study demonstrated that tempol, a radical scavenger, improved FMD 
of STZ rats (Fig. 2), and that more NADPH oxidase subunit p47phox was 
expressed in femoral arteries (Fig. 3A). As well, apocynin significantly 
decreased high glucose-induced ROS production in HCAECs (Fig. 5H); 
indicating that endothelial dysfunction in STZ rats was caused by the 
oxidative stress produced by NADPH oxidase. Moreover, nicorandil 
inhibited expression of NADPH oxidase in STZ rat femoral arteries (Fig. 
3A), and also prevented high glucose-induced ROS production in HCAECs 
(Fig. 6). These results suggest that nicorandil ameliorates endothelial 
dysfunction by decreasing NADPH oxidase which inhibited production of 
ROS. This agreed with a previous report that nicorandil can inhibit 
production of ROS by NADPH oxidase activation in response to 
hypoxia-reoxygenation in human umbilical vein endothelial cells (Tajima et 
al., 2008).  
An increase in ROS production caused by NADPH oxidase in diabetic 
vessels is at least partially mediated by protein kinase C (PKC) and nuclear 
factor-kappa B (NF-B) (Mariappan et al., 2010; Ohshiro et al., 2006). 
Because nicorandil exerts inhibitory effects on PKC activity (Iliodromitis et 
al., 2008) and NF-B activation (Kawamura et al., 2005), nicorandil might 
prevent the increase in NADPH oxidase by inhibiting PKC or NF-B in 
diabetic rats. Moreover, it has been suggested that mitochondrial ROS may 
activate vascular NADPH oxidase through a PKC-dependent process 
(Wenzel et al., 2008A). Eguchi et al suggested that nicorandil inhibits 
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ROS-induced ROS release in the mitochondria of endothelial cells (Eguchi 
et al., 2009). Therefore, nicorandil may inhibit NADPH oxidase by 
protecting mitochondria. 
 
Contribution of eNOS to ROS production in diabetes 
eNOS can produce NO or superoxide. eNOS is uncoupled when BH4, an 
essential cofactor of NOS, is reduced in oxidative states (Landmesser et al., 
2003). As a result, production of superoxide is increased by the eNOS 
monomer; whereas, in the presence of abundant BH4 the eNOS dimer 
produces mainly NO (Landmesser et al., 2004). In the diabetic state, eNOS is 
believed to serve as another source of ROS (Hink et al., 2001; Wenzel et al., 
2008C). High glucose can induce an eNOS uncoupling state due to BH4 
deficiency (Cai et al., 2005), leading to decrease in NO production and 
increase in superoxide production (Hink et al., 2001; Satoh et al., 2008). In 
fact, there are clinical and experimental reports that describe administration 
of BH4 to improve endothelial function (Heitzer et al., 2000; Pieper, 1997). In 
the present study, the expression of GCH-1, a major enzyme for BH4 
synthesis, was decreased in STZ rats (Fig. 3D). This was consistent with the 
decrease in eNOS dimer/monomer ratio (Fig. 3C). These results suggest that 
ROS production in STZ rats could be derived from an uncoupled state of 
eNOS. In fact, the NOS inhibitor L-NAME completely inhibited production 
of ROS induced by high glucose treatment in HCAECs (Fig. 5D), suggesting 
that ROS production in STZ rats was derived mainly from eNOS.  
 Nicorandil is known from several studies to increase the expression 
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and activity of eNOS. This occurs not only in normal rat hearts (Horinaka et 
al., 2001) but also in several disease models such as salt-sensitive Dahl rats 
(Horinaka et al., 2006; Xu et al., 2005), myocardial infarcted rats (Horinaka 
et al., 2004) and monocrotaline-induced pulmonary hypertensive rats (Hongo 
et al., 2005). Increased release of NO by nicorandil was correlated with 
enhancement of eNOS phosphorylation in cultured rat cardiac fibroblasts 
(Liou et al., 2011). The increase in eNOS expression is related to the 
improvement of symptoms. On the other hand, the present study 
demonstrated that nicorandil decreased the increase in total eNOS 
expression in STZ rats (Fig. 3B) and improved endothelial function. To our 
knowledge, this is the first demonstration that nicorandil inhibits the 
increase in expression of eNOS in diabetic rats. There is a possibility that 
nicorandil inhibited the expression of eNOS. In diabetic rats, hyperglycemia 
increased superoxide production by activating mitochondrial electron 
transport chain (Nishikawa et al., 2000), which activated PKC, resulting in 
upregulation of eNOS in the endothelium (Creager et al., 2003; Hink et al., 
2001). Because nicorandil and diazoxide can reduce the mitochondrial ROS 
production (Ozcan et al., 2002), the inhibition of mitochondrial ROS by 
nicorandil may serve to inhibit the increase in eNOS expression in STZ rats. 
Further investigation is required to clarify the mechanisms by which 
nicorandil regulates eNOS expression. 
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Chapter 2 
 
 
Studies of effect of nicorandil  
on paclitaxel-induced endothelial dysfunction in rats 
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2-1. Introduction 
It is well known that the endothelium plays an important role in the 
regulation of vascular tone via release of factors such as NO, prostaglandin I2, 
endothelium-derived hyperpolarization factor (EDHF), and endothelin. 
Endothelial dysfunction predicts adverse cardiac events in patients with 
coronary artery disease (Kitta et al., 2009). It is mainly caused by loss of NO 
that occurs from several pathological conditions, such as atherosclerosis, 
hypertension, and diabetes. Recently, DES has been considered as another 
potential cause of endothelial dysfunction, despite their successful use in the 
treatment of ischemic heart diseases by providing dramatic reduction in 
in-stent restenosis (Dawkins et al., 2005; Stone et al., 2005; Stone et al., 
2004). Paclitaxel, one of the major drugs used in DES, is known to cause 
endothelial dysfunction in humans (Shin et al., 2007) and swine (Pendyala et 
al., 2009) because it induces apoptosis and cytotoxicity in human coronary 
artery endothelial cells (Wessely et al., 2007). 
Nicorandil, an anti-anginal drug with KATP channel opening and 
nitrate-like activity, was shown in the IONA (IONA study group, 2002) and 
JCAD (Horinaka et al., 2010) studies to improve the prognoses of patients 
with ischemic heart disease by a pharmacological preconditioning effect 
(Horinaka, 2011). In both clinical settings and animal studies, it also has 
been reported that nicorandil reduced cardiac events partially by protecting 
endothelium. Nicorandil improved FMD (an indicator of endothelial 
function) in patients with ischemic heart disease (Sekiya et al., 2005) or with 
cardiovascular risk factors (Ishibashi et al., 2008). And it reduced myocardial 
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no-reflow in swine by protecting endothelial function (Zhao et al., 2006). In 
chapter 1, I demonstrated that nicorandil protected endothelial function in 
diabetic rats. However, there are no reports that nicorandil provides 
protection from endothelial dysfunction caused by paclitaxel. 
In the next study, I investigated the protective effect of nicorandil on 
paclitaxel-induced endothelial dysfunction. I also sought the mechanisms 
underlying this protective effect in association with NO bioavailability in 
vascular endothelial cells. 
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2-2. Materials and Methods 
Chemicals 
Nicorandil was synthesized in the Chugai Organic Chemistry 
Laboratory. Paclitaxel and the other reagents were analytical grade and 
purchased from Wako Pure Chemicals Co. Tempol, 5-hydroxydecanoate 
(5-HD) and 1H-[1,2,4] oxadiazolo [4,3-a]quinoxalin-1-one (ODQ), isosorbide 
dinitrate (ISDN) and diazoxide were obtained from Sigma-Aldrich. 
Nitroglycerin came from Nippon Kayaku (Tokyo, Japan) and acetylcholine 
was supplied by Daiichi-Sankyo (Tokyo, Japan).  
Paclitaxel was dissolved in 50% dimethylformamide, 25% Cremophor 
EL, and 25% distilled water. Diazoxide and ISDN were suspended in 3% gum 
arabic solution. Nitroglycerin and acetylcholine were dissolved in, and 
diluted with, 0.9 % saline solution. All other drugs were dissolved in distilled 
water just before the experiment. The concentrations of paclitaxel used in 
this study were chosen on the basis of studies published previously (Kim et 
al., 2004; Wessely et al., 2007). 
 
Animals 
Male Sprague Dawley rats (250–300 g) were used. All rats were fed 
ordinary laboratory chow and allowed free access to water under a constant 
light and dark cycle of 12 h. The rats were anesthetized with an 
intraperitoneal injection of pentobarbital (50 mg/kg) and adequate 
anesthetic depth was monitored by pinching the toe. An osmotic pump 
(model 2ML1; Durect Corp., Cupertino, CA, USA) was implanted 
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subcutaneously into a small pouch between the shoulder blades to 
continuously infuse paclitaxel (0.5, 1.5, 5 mg/kg/day). Bupivacaine (5 mg/mL) 
was applied topically to the skin wound. For the vehicle group, the osmotic 
pump containing vehicle (50% dimethylformamide, 25% Cremophor EL, and 
25% distilled water) was subcutaneously implanted. Nicorandil (15 
mg/kg/day) and tempol (20 mg/kg/day) were dissolved in drinking water and 
administered for 1 week, from just after implantation of the osmotic pump. 
Diazoxide (15 mg/kg) and ISDN (15 mg/kg) were administered by gastric 
gavage once a day for 1 week from just after implantation. FMD was 
measured in rats 1 week after implantation of the osmotic pump.  
All animal procedures were conducted in accordance with Chugai 
Pharmaceutical’s ethical guidelines for animal care, and all experimental 
protocols were approved by the Animal Care Committee of the institution 
and conform to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health. All animals were 
euthanized by exsanguination under anesthesia after experiments. 
 
Measurements of endothelial function in live rats 
FMD was measured in living rats as described in Chapter 1. In this 
study, vasodilation induced by acetylcholine was also evaluated as another 
indicator of endothelial function. Acetylcholine (3 ng) was injected into the 
aorta just proximal to the iliac bifurcation after femoral artery was 
visualized using a high-resolution ultrasound system in anesthetized rats. 
The change in diameter of femoral artery was monitored until 1 min after 
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injection. 
 
Real-time PCR analysis in rat femoral arteries 
After measurement of FMD, femoral arteries were harvested and 
stored in RNAlater solution (Ambion, Austin, TX, USA) until RNA isolation 
was performed. Tissues were homogenized with a Micro Smash homogenizer 
(Tomy Digital Biology, Tokyo, Japan), and total RNA was isolated using an 
RNeasy Fibrous Tissue kit (Qiagen, Dusseldorf, Germany). Real-time PCR 
was performed using TaqMan Gene Expression Assays for NADPH oxidase 
components p47phox and gp91phox in an ABI PRISM 7500 Sequence Detection 
System (Applied Biosystems, Carlsbad, CA, USA). Gene expression was 
normalized to the endogenous control, -actin. 
 
Measurement of ROS in mouse testicular arteries 
In vivo ROS production was monitored by the fluorescent probe, 
dihydrorhodamine 123 hydrochloride (Wako Pure Chemical) according to the 
method as previously described (Eguchi et al., 2009). Briefly, male ICR mice 
(10 to 11 weeks old) were anesthetized with pentobarbital (50 mg/kg, i.p.). 
Endothelial cells were observed by isolectin B4 labeled with FITC: an 
endothelial cell marker specific to mice (Vector Lab, Burlingame, CA, USA). 
After the testicular artery (approx. 200 μm in diameter) was carefully 
exposed, dihydrorhodamine 123 (2.5 mg/kg) was given intravenously, 
followed by intravenous administration of FITC-labeled isolectin B4 (1.25 
mg/kg). The fluorescence intensity was observed by an ultrafast laser 
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confocal microscope equipped with a piezoelectric motor control unit, and 
was recorded as arbitrary units (au). Under pentobarbital anesthesia, mice 
were subcutaneously implanted osmotic pump (model 1007D; Durect Corp.) 
with body temperature kept stable and monitoring adequate anesthetic 
depth by pinching the toe. Paclitaxel (5 mg/kg/day), was infused continuously 
from the osmotic pump. Nicorandil (15 mg/kg/day) was administrated in 
drinking water from just after infusion of paclitaxel. 
 
Measurements of ROS in HCAECs 
To measure production of ROS, HCAECs were seeded onto plastic 
dishes (1×105 cells/2 mL/dish) and cultured in monolayers in a 5% CO2 
humidified incubator at 37°C. After overnight incubation, paclitaxel (10 
ng/mL) was added to the culture medium for 24 h. Nicorandil (100 M), 5-HD 
(500 M), and ODQ (20 M) were added over the same period. The cellular 
level of ROS production was evaluated as described in Chapter 1. 
  
Western blot analysis in HCAECs 
Paclitaxel (10 ng/mL) was added to the culture medium for 24 h. 
Nicorandil (100 M) was added over the same period. Then, cells were 
harvested and used for western blotting. Equal amounts of protein extract 
were separated on 10% SDS-polyacrylamide gel and immobilized on PVDF 
membranes. The membranes were incubated with anti-eNOS (Santa Cruz 
Biotechnology), anti-phospho-eNOS (Cell Signaling Technology, Danvers, 
USA) and anti--actin antibodies. Immunoreactive signals were detected 
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using a ChemiDoc XRS system (Bio-Rad). 
 
Measurements of NO in HCAECs 
Intracellular NO was assessed with diaminofluorescein-2 diacetate 
(DAF-2DA; Sekisui medical, Tokyo, Japan) fluorescence probe (10 mol/L) 
(Wang et al., 2008). Briefly, HCAECs were incubated with PBS containing 10 
M DAF-2 in the dark for 30 min at 37 °C, and then washed twice with PBS. 
Fluorescence intensity was measured by spectrofluorophotometry 
(SpectraMax Gemini XS (Molecular Devices, CA, USA) with excitation and 
emission wavelengths of 485 and 545 nm, respectively. 
 
Statistical analyses 
All data are expressed as mean ± SE. The n values refer to the 
number of individual animals in each experiment. The statistical 
significance of differences was determined by using the Tukey Multiple 
Comparison Test. Probability (P) values less than 0.05 were considered 
significant. 
  
  
42 
 
2-3. Results 
Measurements of FMD in rats 
Endothelial function was evaluated by measuring FMD in rat 
femoral arteries. The femoral arterial flow velocity was 121.2  10.3 mm/s at 
baseline in rats treated with vehicle (Fig. 7A). When the common iliac artery 
was occluded for 5min and reperfused, the flow velocity increased instantly 
(i.e. reactive hyperemia) to 176.1  3.7 mm/s (Fig. 7B). The flow velocity 
decayed rapidly to baseline values at around 3 min (Fig. 7C). The increase in 
flow velocity was associated with the delayed increase in femoral arterial 
vasodilation. The femoral arterial diameter increased from 0.40  0.01 mm 
(Fig 7D) to 0.48  0.01 (Fig 7E) at 1 min after reperfusion. The percentage 
increase in arterial diameter (vasodilation) peaked at 1 min (Fig. 7F). This 
delayed vasodilation is FMD. 
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Figure 7. Post-ischemic reactive hyperemia and vasodilation of the rat 
femoral artery 
Original Doppler flow velocity tracings at baseline (A) and at onset of reperfusion after 5 
min occlusion of the common iliac artery (B). (C) Time course of peak flow velocity after 
5 min ischemia. Representative ultrasound image of the femoral artery at baseline (D) 
and 1 min after reperfusion (E). Longitudinal sections of the rat femoral artery were 
visualized with a high-resolution ultrasound probe placed on the upper thigh. (F) Time 
course of vasodilation (percentage increase in arterial diameter) after 5 min ischemia (n 
= 5).  Arrow indicates femoral artery. Scale bars = 1 mm. 
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Effects of nicorandil on reduced FMD in rats treated with paclitaxel 
I evaluated the influences of paclitaxel and nicorandil on FMD of rat 
femoral artery. Continuous subcutaneous infusion of paclitaxel (0.5, 1.5, 5 
mg/kg/day, 7 days) reduced FMD in a dose-dependent manner (Fig. 8A). 
Reactive hyperemia was also evaluated as an inducer of FMD in the femoral 
artery to confirm that stimulation to the endothelium was similar among the 
groups. As a result, reactive hyperemia was similar among the groups (Fig. 
8B). NTG was administered to evaluate endothelium-independent 
vasodilation because it was possible that paclitaxel impaired vascular 
smooth muscle function which influenced FMD. NTG-induced vasodilation 
was similar among the groups (Fig. 8C). These results imply that paclitaxel 
impaired endothelial function without changing contractility in vascular 
smooth muscle (Control, 21.6 ± 3.2; Paclitaxel [5 mg/kg/day], 7.1 ± 1.7%, Fig. 
8A). On the other hand, co-treatment with nicorandil prevented the decrease 
in FMD caused by paclitaxel (15.5 ± 2.5%) without changing flow velocity or 
NTG-induced vasodilation (Fig. 8B, C). In the current study I found that 
treatment with paclitaxel and nicorandil for 1 week did not affect body 
weight, blood pressure or heart rate relative to rats treated with vehicle 
(Table 2). 
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Figure 8. Effects of nicorandil on endothelial function impaired by paclitaxel 
as evaluated by FMD 
(A) Dose-dependent impairment of FMD by paclitaxel (0.5, 1.5, 5.0 mg/kg/day; 1 week) 
and the effects of nicorandil (15 mg/kg/day; 1 week) on paclitaxel-induced impairment of 
FMD. Peak velocity (B) and NTG-induced vasodilation (C) were similar among groups. 
*P < 0.05 vs. control; #P < 0.05 vs. paclitaxel (5 mg/kg/day) (n = 5–9). 
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Table 2. Body weight, blood pressure and heart rate at 1 week after 
paclitaxel administration 
 
 
Vehicle 
Paclitaxel 
0.5 1.5 5.0 
5.0 
+ Nicorandil 
N 5 6 5 9 7 
Body weight 
(g) 
330.9 ± 13.9 337.3 ± 3.5 343.5 ± 6.6 322.0 ± 16.1 293.3 ± 14.6 
Systolic blood 
pressure 
(mmHg) 
134.9 ± 3.5 136.6 ± 5.0 121.8 ± 5.0 129.2 ± 2.5 122.7 ± 3.4 
Heart rate 
(bpm) 
362.6 ± 8.1 369.2 ± 8.5 378.3 ± 8.0 369.1 ± 6.3 394.0 ± 9.5 
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Effects of nicorandil on vasodilation induced by acetylcholine in rats treated 
with paclitaxel 
Acetylcholine-induced vasodilation serves as an indicator of 
endothelial function because it can induce NO-dependent vasodilation by 
eNOS activation in endothelium. Therefore, I next evaluated the influence of 
paclitaxel and nicorandil on acetylcholine-induced vasodilation in living rats. 
In vehicle-treated rats, local administration of acetylcholine into the iliac 
artery led to femoral arterial vasodilation. Peak dilation was at 10 sec and 
rapidly decayed to baseline by approximately 60 sec (Fig. 9A). In rats treated 
with paclitaxel (5 mg/kg/day), acetylcholine induced significantly less 
dilation in the femoral artery (Control, 12.7 ± 2.1%; Paclitaxel, 3.9 ± 1.1%). 
On the other hand, nicorandil significantly prevented the decrease in 
acetylcholine-induced vasodilation by paclitaxel (Paclitaxel + Nicorandil, 
12.5 ± 3.5%, Fig. 9B). These results were consistent with the FMD 
measurements (Fig. 8A), indicating that nicorandil surely prevented 
endothelial dysfunction caused by paclitaxel.  
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Figure 9. Effects of nicorandil on endothelial function impaired by paclitaxel 
as evaluated by acetylcholine injection 
Acetylcholine was injected into the common iliac artery through an intra-aortic catheter. 
Time course (A) and mean percentage increase in arterial diameter at 10 sec after 
acetylcholine injection (B) was evaluated at the femoral artery. *P < 0.05 vs. control; #P 
< 0.05 vs. paclitaxel (5 mg/kg/day) (n = 7–8). 
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Effects of diazoxide, ISDN, and tempol on FMD in rats treated with 
paclitaxel 
Because nicorandil is known to exert multiple actions, such as KATP 
channel opening and nitrate-like activity, it was important to determine 
which action was more important in endothelial protective effect of 
nicorandil. Diazoxide, a mitochondrial KATP channel opener, was used 
instead of nicorandil. As shown in Figure 10, diazoxide prevented 
significantly the decrease in FMD caused by paclitaxel, suggesting that 
opening mitochondrial KATP channels is important in endothelial protection. 
Conversely, ISDN, a nitrate which serves as an NO donor, had no effect (Fig. 
10). These results suggest that mitochondrial KATP channel opening was 
more important than nitrate-like activity in endothelial protection. 
Furthermore, I also examined the involvement of oxidative stress in 
paclitaxel-induced endothelial dysfunction. Tempol, a ROS scavenger, also 
prevented the decrease in FMD of rats treated with paclitaxel (Fig. 10). This 
result could mean that paclitaxel caused endothelial dysfunction by 
oxidative stress. 
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Figure 10. Effects of diazoxide, ISDN and tempol on FMD impaired by 
paclitaxel 
Diazoxide (15 mg/kg/day) and ISDN (15 mg/kg/day) were suspended in 3% gum arabic 
solution and administrated by gastric gavage once a day for 1 week. Tempol (20 
mg/kg/day, p.o.) was administrated in drinking water for 1 week. *P < 0.05 vs. control; 
#P < 0.05 vs. paclitaxel (5 mg/kg/day) (n = 5–7). 
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Effects of nicorandil on gene expression of NADPH oxidase in femoral 
arteries of rats treated with paclitaxel 
Because the involvement of oxidative stress in paclitaxel-endothelial 
dysfunction was indicated in Figure 10, I examined the effect of nicorandil on 
the expression of NADPH oxidase which is a major source of ROS. The 
mRNA expressions of p47phox and gp91phox, the major components of NADPH 
oxidase, increased significantly in femoral arteries isolated from rats treated 
with paclitaxel (Fig. 11). On the other hand, nicorandil prevented 
significantly the increase in p47phox expression (Fig. 11A), and also limited 
the increase in gp91phox expression (Fig. 11B, P = 0.09 vs. paclitaxel). These 
results suggest that nicorandil could prevent oxidative stress induced by 
paclitaxel through inhibiting NADPH oxidase. 
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Figure 11. Effects of nicorandil on changes in expression of p47phox and 
gp91phox mRNA  induced by paclitaxel in rat femoral arteries 
p47phox (A) and gp91phox (B) expression levels in femoral arteries were measured using 
real-time PCR. Data are shown as subunit/-actin ratio. *P < 0.05 vs. control; #P < 0.05 
vs. paclitaxel (5 mg/kg/day) (n = 8). 
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Effects of nicorandil on production of ROS in testicular arteries of mice 
treated with paclitaxel 
Because nicorandil prevented the increase in NADPH oxidase by 
paclitaxel, I examined the effect of nicorandil on paclitaxel-induced ROS 
production. As shown in Figure 12, the fluorescence intensity of 
dihydrorhodamine 123 hydrochloride in mice treated with paclitaxel was 1.6 
times greater than in mice treated with vehicle. On the other hand, 
co-treatment with nicorandil significantly inhibited any increase in 
fluorescence intensity (control, 33.0 ± 0.5; paclitaxel, 52.2 ± 1.1; paclitaxel + 
nicorandil, 44.3 ± 1.0 au). This result suggests that nicorandil could prevent 
paclitaxel-induced ROS production. 
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Figure 12. Effect of nicorandil on oxidative stress in mice caused by 
paclitaxel 
Production of reactive oxygen species in mouse testicular arteries by paclitaxel was 
measured using dihydrorhodamine 123 hydrochloride. Representative images show 
fluorescence in control (A), 7 days after administration of paclitaxel (B), and 7 days 
after nicorandil was co-administered with paclitaxel (C). Scale bar =25 μm. (D) Each 
column denotes mean fluorescence intensity from 3 mice. Paclitaxel especially 
increased the fluorescence intensity at the edge of the spindle-shaped vascular 
endothelial cells (B). *P < 0.05 vs. control; #P < 0.05 vs. paclitaxel (5 mg/kg/day). 
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Effects of nicorandil on production of ROS, NO release and eNOS 
phosphorylation induced by paclitaxel in HCAECs 
I also examined the effect of nicorandil on paclitaxel-induced ROS 
production in HCAECs. Paclitaxel (10ng/mL) significantly increased DCF 
fluorescence compared with control. Nicorandil, in turn, significantly 
inhibited the increase in DCF fluorescence by paclitaxel (Fig. 13). This result 
indicated that nicorandil prevented paclitaxel-induced ROS production. A 
further experiment determined whether KATP channel opening or nitrate-like 
activity was more important in the anti-oxidative effect of nicorandil. The 
anti-oxidative potential of nicorandil was abolished by co-treatment with 
5-HD, a mitochondrial KATP channel inhibitor (Fig. 14A), but not by 
co-treatment with ODQ, a specific inhibitor of soluble guanylate cyclase 
(Fig. 14B). Treatment with 5-HD alone increased DCF fluorescence 
compared with control (Fig. 14A), whereas nicorandil or ODQ alone did not 
affect DCF fluorescence (Fig. 13, 14B). Opening mitochondrial KATP channels 
may be important for the anti-oxidative effect of nicorandil.  
Next, I examined the influence of paclitaxel and nicorandil on NO 
production in HCAECs. Paclitaxel (10 ng/mL) significantly decreased DAF-2 
fluorescence intensity compared with control. This result indicated that 
paclitaxel decreased NO production in HCAECs. Nicorandil tended to inhibit 
the decrease in DAF-2 fluorescence intensity induced by paclitaxel (Fig. 15A). 
Nicorandil alone had no effect on fluorescence intensity. On the other hand, 
there was no significant difference in the phosphorylation of eNOS protein 
among the groups in HCAECs (Fig. 15B). 
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Figure 13. Effects of nicorandil on oxidative stress induced by paclitaxel in 
HCAECs 
The images show representative fluorescences in control (A), after 24 h treatment with 
paclitaxel (10 ng/mL) (B), paclitaxel + nicorandil (100 M) (C), and nicorandil alone (100 
M) (D). Fold changes in DCF fluorescence intensity are provided as the normalized 
ratio to control (E). Intracellular production of reactive oxygen species was measured 
with confocal microscopy after 45 min DCF (10 M) label as described in the Methods. 
Nicorandil inhibited paclitaxel-induced fluorescence intensity in HCAECs. *P < 0.05 vs. 
control; #P < 0.05 vs. paclitaxel. Each column denotes mean fluorescence intensity of 20 
cells/dish from 3 dishes. Scale bar = 100 µm. 
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Figure 14. Effects of 5-HD and ODQ on inhibition of nicorandil against 
oxidative stress induced by paclitaxel in HCAECs 
Co-treatment with 5-HD (500 M; 24 h), a mitochondrial KATP channel inhibitor (A), but 
not by co-treatment with ODQ (20 M; 24 h), a specific inhibitor of soluble guanylate 
cyclase (B) abolished the inhibitory effects of nicorandil (100 M) on the increase in 
oxidative stress induced by paclitaxel (10 ng/mL). Fold changes in DCF fluorescence 
intensity are provided as the normalized ratio to vehicle control. Intracellular 
production of reactive oxygen species was measured after 45 min DCF (10 M) label 
with confocal microscopy as described in the Methods. *P < 0.05 vs. control; #P < 0.05 vs. 
paclitaxel; † P < 0.05 vs. paclitaxel with nicorandil. Each column denotes mean 
fluorescence intensity of 20 cells/dish from 3 dishes.  
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Figure 15. Effects of nicorandil on fluorescent intensity of DAF-2 and 
phospho-eNOS expression in cultured HCAECs 
(A) Each column denotes mean fluorescence intensity of DAF-2 from 6 dishes. (B) 
Phospho-eNOS expression levels in HCAECs were measured by western blotting. Data 
are shown as phosphor-eNOS/eNOS ratio from 3 dishes. *P < 0.05 vs. control. 
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2-4. Discussion 
Although paclitaxel-eluting stents (PES) dramatically reduces in-stent 
restenosis, paclitaxel leads to endothelial dysfunction. This Chapter 
investigated the protective effects of nicorandil on endothelial dysfunction 
induced by paclitaxel and the underlying mechanisms using FMD in 
anesthetized rats. The main finding was that paclitaxel decreased FMD in 
anesthetized rats by both increasing oxidative stress and decreasing NO 
production. Furthermore, based on the results of functional FMD, ROS 
production, mRNA expression, NO synthesis and eNOS phosphorylation, the 
present study also demonstrated that nicorandil protects against endothelial 
dysfunction mainly by inhibiting of production of ROS. It is also suggested 
that this beneficial effect of nicorandil could be exerted through opening 
mitochondrial KATP channel. 
 
Contribution of oxidative stress to endothelial dysfunction induced by 
paclitaxel 
It has been postulated that paclitaxel causes endothelial dysfunction by 
reducing NO availability. A critical determinant of endothelial function is the 
balance between NO and ROS. The availability of endothelium-derived NO 
can be limited by enhanced formation of ROS (Landmesser et al., 2004; 
Muller and Morawietz, 2009). NO can be trapped with ROS in a very rapid 
reaction, forming peroxynitrite and reducing available NO (Gryglewski et al., 
1986). An earlier report indicated that NADPH oxidase is a significant 
source of the superoxide produced following treatment with paclitaxel, and 
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that an NADPH oxidase inhibitor or suppression of gp91phox by siRNA 
significantly attenuated cell death induced by paclitaxel (Jang et al., 2008). 
Thrombotic processes may also be enhanced when paclitaxel reduces NO 
availability, because less NO availability not only attenuates vasodilation 
but also adversely affects anti-thrombotic processes such as reduced 
leukocyte adhesion, platelet adhesion, aggregation, and expression of 
plasminogen activator inhibitor (PAI-1) (Landmesser et al., 2004). Indeed, 
paclitaxel has increased the expression of PAI-1 mRNA in HCAECs 
(Muldowney et al., 2007). Our findings were consistent with those earlier 
reports. In this study, paclitaxel increased ROS production in both in vivo 
mice (Fig. 12) and HCAECs (Fig. 13, 14), with concurrent increases in mRNA 
expression of NADPH oxidase (p47phox and gp91phox, Fig. 11) in rat femoral 
arteries. Moreover, tempol prevented the decrease in FMD by paclitaxel in 
rat femoral arteries (Fig. 10). On the other hand, paclitaxel did not change 
eNOS phosphorylation in HCAECs despite the decrease in NO release (Fig. 
15). These data clearly suggest that paclitaxel induces endothelial 
dysfunction by limiting the availability of NO derived from endothelium by 
increasing ROS production. Earlier reports indicated that paclitaxel induced 
endothelial dysfunction in humans (Shin et al., 2007), animals (Pendyala et 
al., 2009; Pires et al., 2007), and cultured cells (Pasquier et al., 2004; Wessely 
et al., 2007) through apoptosis by increasing the level of pro-apoptotic mRNA 
transcripts, although the relationship between reduction of NO availability 
induced by paclitaxel and endothelial dysfunction was not fully revealed. 
Tawa et al. found that hypoxia-induced ROS production in smooth muscle 
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cells impaired NO donor-mediated relaxation in endothelium-denuded 
monkey coronary arteries (Tawa et al., 2011). This means that ROS has the 
potential to impair not only the NO bioavailability but also vascular smooth 
muscle function. However, in this study, relaxation induced by nitroglycerin 
was unimpaired by paclitaxel (Fig. 8C), implying that paclitaxel-induced 
ROS production did not impair smooth muscle function in this study. The 
reasons for this discrepancy may lie in differences in amount of ROS 
production or in the methods used to measure vascular relaxation. 
 
Contribution of KATP channel to endothelial protective effect of nicorandil 
Earlier studies suggested that nicorandil protects endothelium through 
its anti-oxidative effect. Based on experimental results showing that 
nicorandil reinforced the anti-aggregatory activity of endothelial cells by 
reducing ROS production under hypoxia–reoxygenation conditions, Tajima 
et al. suggested that the protective effect of nicorandil on endothelium was 
mediated by inhibiting NADPH oxidase activity by opening mitochondrial 
KATP channel (Tajima et al., 2008). The present study further indicated that 
nicorandil prevents paclitaxel-induced endothelial dysfunction by reducing 
oxidative stress by mitochondrial KATP channel opening. Diazoxide, another 
mitochondrial KATP channel opener, prevented reduction of FMD by 
paclitaxel (Fig. 10), and the reduction of ROS by nicorandil was inhibited in 
HCAECs by 5-HD, a mitochondrial KATP channel blocker (Fig. 14A). 
Interestingly, treatment with 5-HD alone increased oxidative stress (Fig. 
14A), suggesting that the mitochondrial KATP channel is important in 
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regulating oxidative stress in the endothelium that is induced by paclitaxel. 
In fact, ISDN did not prevent the decrease in FMD by paclitaxel (Fig. 10), 
and ODQ did not inhibit the decrease in ROS by nicorandil in HCAECs (Fig. 
14B). Thus, nicorandil might improve endothelial dysfunction caused by 
paclitaxel through KATP channel activation. The action of nicorandil was not 
dependent on its nitrate-like activity, although it cannot be ruled out 
completely.  
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General Discussion 
 In the Chapter 1, I demonstrated that nicorandil ameliorated 
endothelial dysfunction as evaluated by FMD in STZ rats through an 
anti-oxidative effect exerted by normalizing p47phox and eNOS uncoupling. In 
the Chapter 2, I demonstrated that nicorandil ameliorated endothelial 
dysfunction caused by paclitaxel as evaluated by FMD and may improve NO 
bioavailability by reducing oxidative stress via KATP channel activation. In 
the course of these experiments, it became clear that endothelial dysfunction 
could be quantified by measuring FMD, and that nicorandil prevented 
endothelial dysfunction via its anti-oxidative effect by activating 
mitochondrial KATP channel. These results suggest that nicorandil might be 
effective in relieving endothelial dysfunction and improve the prognoses of 
angina patients with diabetes or DES implantation. 
  
Action mode of nicorandil 
Because nicorandil is known to open KATP channel and have nitrate 
like activity, it was of interest which action contributed to its anti-oxidative 
and endothelial protective effects. Earlier reports indicated the importance 
of KATP channel in anti-oxidative properties and endothelial protection. 
Nicorandil, but not ISDN improved FMD in patients with ischemic heart 
disease (Sekiya et al., 2005). Eguchi et al. suggested that nicorandil 
prevented thrombi by activating mitochondrial KATP channels and inhibiting 
ROS-induced ROS release in the mitochondria of endothelial cells (Eguchi et 
al., 2009). Ozcan et al. also found that nicorandil prevents oxidative stress by 
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opening mitochondrial KATP channels (Ozcan et al., 2002). In the Chapter 2, I 
also demonstrated that nicorandil and diazoxide improved FMD in rats 
treated with paclitaxel. Furthermore, ROS production typically reduced by 
nicorandil was inhibited by 5-HD in HCAECs treated with paclitaxel. This 
affirmed that KATP channels are important to the anti-oxidative effect and 
endothelial protection afforded by nicorandil. Inefficient transport of 
electrons due to altered mitochondrial membrane potentials can increase 
electron leakage and ROS production (Gupta et al., 2009). Consequently, 
mitochondrial ROS can activate vascular NADPH oxidase (Wenzel et al., 
2008B). Therefore, nicorandil might exert its anti-oxidative effect by 
protecting mitochondria by mitochondrial KATP channel activation. Indeed, 
nicorandil and diazoxide are known to limit production of mitochondrial ROS 
(Ozcan et al., 2002). Tajima et al. revealed that the protective effect of 
nicorandil on the endothelium was mediated by inhibiting NADPH oxidase 
activity via opening mitochondrial KATP channels (Tajima et al., 2008). 
Although it cannot be ruled out completely, the action of nicorandil in this 
study did not depend on its nitrate-like activity. As described in Chapter 2, 
ISDN did not prevent a decrease in FMD caused by paclitaxel, and ODQ did 
not inhibit anti-oxidative effect of nicorandil in HCAECs.  
 
Utility of FMD measurement in rats 
Herein, I observed that FMD was clearly reduced in STZ rats without a 
change in endothelium independent relaxation induced by NTG (Chapter 1). 
This was consistent with earlier reports showing that acetylcholine-induced 
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relaxation was diminished in isolated vascular beds from STZ rats without 
affecting endothelium-independent relaxation (Gupte et al., 2010; Pieper, 
1997; Pieper et al., 1996). In Chapter 2, moreover, FMD was reduced in rats 
treated with paclitaxel, which was consistent with reduction of 
acetylcholine-induced vasodilation. It is possible measuring FMD in living 
rats is a useful experimental tool to estimate endothelial dysfunction in 
serious vascular diseases. 
Evaluation of endothelial function by measuring FMD in living rats 
seems to have at least 3 potential advantages. First, FMD measurements 
can evaluate endothelial function under both physiological and pathological 
conditions. Endothelial function can be influenced either by NO availability 
or by sensing of shear stress (Yamamoto and Ando, 2011). NO availability is 
determined by NO production that depends on the expression level and the 
enzyme activity of eNOS, both of which are modulated by various humoral 
factors such as increased ROS (Landmesser et al., 2004), increased 
asymmetric dimethylarginine (ADMA) (Cooke, 2000; Landmesser et al., 
2004), depletion of tetrahydrobiopterin (Crabtree et al., 2011; Landmesser et 
al., 2003), and an increase in advanced glycation end products (Rojas et al., 
2000). In addition, NO can be trapped with ROS in a very rapid reaction, 
forming peroxynitrite and reducing available NO. All these lines of evidence 
combined to indicate that the results from isolated arterial strips may 
underestimate the precise in vivo situation of endothelial dysfunction, 
because these humoral factors are absent for experiments in isolated tissues. 
Moreover, shear stress induced by blood flow stimulates NO production from 
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the concerted action of multiple mechanotransducer molecules, including the 
glycocalyx, integrins, and caveolae (Yamamoto and Ando, 2011), which can be 
reduced under certain genetic or pathological conditions. Second, rats are 
better experimental material than large animals in many situations, even 
though FMD can be applied not only for clinical diagnosis but also in 
experiments in large animals such as dogs (Jones et al., 2011) and pigs 
(Weber et al., 2011). Rats are smaller, so experiments can be conducts with 
fewer amount of drug. Furthermore, many rat disease models are available. 
Finally, FMD makes it possible to measure endothelial function repeatedly in 
individual rats. Time-dependent changes in pathological conditions or 
chronic effects of drugs on endothelial function can be traced in the same rat 
by permanently implanting an iliac artery occluder. Therefore, in addition to 
classical endothelial function measurement methods in isolated arteries, 
FMD in living rats should provide useful information to not only elucidate 
endothelial physiology and pathology but also to ascertain the roles of 
endothelial protective agents. 
 
Clinical significance 
In the IONA trial, nicorandil significantly improved prognoses by 
reducing the incidence of major coronary events (IONA study group, 2002). 
One of the mechanisms underlying the improvement was explained as 
pharmacological preconditioning (Tsuchida et al., 2002). Recent clinical 
studies have suggested that the protective effects of nicorandil against 
endothelial dysfunction would be another possible mechanism because 
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endothelial dysfunction is a risk factor for cardiovascular disease. It has been 
reported in studies of patients with cardiovascular risk factors that 
long-term administration of nicorandil improves FMD (Ishibashi et al., 2008; 
Ono et al., 2004; Sekiya et al., 2005) and that this improvement was by 
reducing oxidative stress (Ishibashi et al., 2008; Ono et al., 2004). 
In diabetic patients, morbidity and mortality rise due to vascular 
complications such as atherosclerosis, retinopathy and nephropathy, 
triggered by endothelial dysfunction. Glycaemic control agents, statins and 
renin-angiotensin system inhibitors ameliorate endothelial dysfunction 
(Potenza et al., 2009), thereby improving prognosis. In this study of diabetic 
rats, nicorandil protected against endothelial dysfunction by inhibiting 
production of ROS without glycaemic control. This may mean that nicorandil 
can improve the prognoses of patients with ischemic heart disease and 
diabetic complications not only through pharmacological preconditioning, 
but also by protecting the endothelium. In fact, the IONA (IONA study group, 
2004) and JCAD (Horinaka et al., 2010) studies demonstrated that 
nicorandil improves the prognoses of patients with ischemic heart disease 
and diabetes. 
As described in Chapter 2, nicorandil was found to prevent 
paclitaxel-induced endothelial dysfunction by reducing oxidative stress. 
Therefore, nicorandil may have favorable effects on endothelial dysfunction 
in PES-implanted patients as well as in patients with other cardiovascular 
risk factors. Clinical studies are needed to assess the clinical implications of 
our findings. 
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Conclusions 
 Nicorandil could limit endothelial dysfunction caused by diabetes or 
paclitaxel through anti-oxidative effects by KATP channel activation. 
Therefore, nicorandil might improve the prognoses of angina patients with 
diabetes or DES implantation.  
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